Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
10:55am, Tuesday, 30'th Dec 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionabl
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock
04:22am, Friday, 12'th Dec 2025
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm's stock in a transaction on Monday, December 8th. The shares
Fulcrum Therapeutics (NASDAQ:FULC) Sees Strong Trading Volume on Analyst Upgrade
02:12am, Thursday, 11'th Dec 2025
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) saw strong trading volume on Wednesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America cur
Market Today: Fed Cut; Oracle, Rivian, Amazon in Focus
05:34pm, Wednesday, 10'th Dec 2025
Guru Stock PicksPaul Tudor Jones has made the following transactions:Reduce in DOMO by 74.59%Sold out in ITAdd in BRY by 6686.5%New position in LDOSStock News F
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
07:48am, Wednesday, 10'th Dec 2025
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 7.8% After Analyst Upgrade
01:36am, Wednesday, 10'th Dec 2025
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report)'s share price traded up 7.8% during trading on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Ban
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
04:01pm, Monday, 08'th Dec 2025
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to im
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results
01:06pm, Monday, 08'th Dec 2025
Fulcrum Therapeutics Inc. (NASDAQ: FULC) stock is surging on Monday, after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at We
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 05'th Dec 2025
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
Acadian Asset Management LLC Grows Stake in Fulcrum Therapeutics, Inc. $FULC
03:17am, Friday, 14'th Nov 2025
Acadian Asset Management LLC raised its position in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) by 63.5% during the second quarter, according to its most recent filing with the SEC. The institutional in
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Nov 2025
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―
